Fufang Biejia Ruangan: A Modern Approach to Liver Fibrosis Therapy
A traditional Chinese medicine preparation that aims to reduce liver stiffness and suppress excessive connective tissue formation.
Fufang Biejia Ruangan: A Modern Approach to Liver Fibrosis Therapy
A traditional Chinese medicine preparation that aims to reduce liver stiffness and suppress excessive connective tissue formation.
About the Product
Fufang Biejia Ruangan (复方鳖甲软肝片) – is a modern herbal formulation of traditional Chinese medicine, developed specifically to support the liver in cases of fibrosis and chronic liver conditions.
Unlike common hepatoprotectors, it targets not only symptoms but one of the key processes — excessive formation of connective tissue, which makes the liver stiff and reduces its function.
Unlike common hepatoprotectors, it targets not only symptoms but one of the key processes — excessive formation of connective tissue, which makes the liver stiff and reduces its function.
About the Product
Fufang Biejia Ruangan (复方鳖甲软肝片) – is a modern herbal formulation of traditional Chinese medicine, developed specifically to support the liver in cases of fibrosis and chronic liver conditions.
Unlike common hepatoprotectors, it targets not only symptoms but one of the key processes — excessive formation of connective tissue, which makes the liver stiff and reduces its function.
Unlike common hepatoprotectors, it targets not only symptoms but one of the key processes — excessive formation of connective tissue, which makes the liver stiff and reduces its function.
How the Product Works
The product helps counter liver fibrosis (scarring).
It softens liver tissue and helps reduce the excessive buildup of connective tissue — a process that contributes to cirrhosis.
It softens liver tissue and helps reduce the excessive buildup of connective tissue — a process that contributes to cirrhosis.
-
High Effectiveness:
When used alongside antiviral therapy, clinical data shows significant improvements:
— Reduction in liver cancer incidence by 51.1% (over 7 years).
— Reduction in liver-related mortality by 89.9% (over 7 years). -
Fibrosis Reversibility:
Demonstrates a notable rate of fibrosis regression, reaching 76.7% over 5 years of therapy. -
Recognition:
Approved in 1999 as the first patented traditional Chinese anti-fibrosis medicine with documented therapeutic activity.
Clinical Studies
-
Studies show that
The LncRNA TUG1–miR-328-3p→PHK SRSF9 axis may be involved in tumor growth in vivo and is effectively regulated by Compound Biejia Ruangan tablets, which have been shown to significantly improve fibrosis progression and help prevent liver cancer development. -
Key network targets of Ruangan Tablets are involved in major biological modules
related to cancer progression, immune regulation, inflammatory responses, and metabolic pathways.
They exert their action by counteracting malignant transformation linked to hepatic fibrosis and modulating the PI3K/Akt/NF-κB signaling pathway.
Product Uniqueness
-
One of the first traditional-medicine-based products officially approved specifically for liver fibrosis therapy in China.
-
Supported by clinical data demonstrating reduced fibrosis markers and improved liver function.
-
A multi-component formula targeting key mechanisms of fibrosis (inflammation, tissue stiffness, activation of hepatic stellate cells).
Liver Support in Fibrosis
— Clinical observations show reduced liver stiffness and favorable dynamics in laboratory markers.
Good Tolerability
— Side effects are rare and usually mild; the product typically does not require discontinuation due to adverse reactions.
Suitable for Long-Term Use
May be used as part of long-term liver support programs — important for chronic liver conditions.
Didn't find what you were looking for?
Send us a link to the product abroad or describe what you are looking for. We will check the possibility of purchasing and delivering this product from abroad.